Association between serum interleukin (IL)-12 level and severity of non-alcoholic fatty liver disease (NAFLD)

1. LI S., HONG M., TAN H., WANG N., FENG Y. Insights into the role and interdependence of oxidative stress in inflammation in liver diseases. Oxid Med Cell Longev. 2016; 2016:4234061.10.1155/2016/4234061Search in Google Scholar

2. ZHAN Y., AN W. Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J Gastroenterol. 2010; 16(37):4652–4660.10.3748/wjg.v16.i37.4652295151520872965Search in Google Scholar

3. LIU Y., ZHONG G., TAN H., HAO F., HU J. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta analysis. Sci Rep. 2019; 9:11124.10.1038/s41598-019-47687-3666840031366982Search in Google Scholar

4. KUMAR A., SINGH AK., PANDA PK., NISCHAL N., SONEJA M. Non-alcoholic fatty liver disease diagnosis, grading and staging; a simplified tool for clinicians. JAM. 2017; 6(1):15–22.10.5958/2319-4324.2017.00003.7Search in Google Scholar

5. LUCI C., VIEIRA E., PERCHET T., GUAL P., GOLUB R. Natural killer cells and type 1 innate lymphoid cells are new actors in non-alcoholic fatty liver disease. Front Immunol. 2019; 10:1192.10.3389/fimmu.2019.01192654684831191550Search in Google Scholar

6. HAMMERICH L, TACKE F. Interleukins in chronic liver disease: lessons learned from experimental mouse models. Clin Exp Gastroenterol. 2014;7:297–306.Search in Google Scholar

7. HAMMERICH L., TACKE F. Interleukins in chronic liver disease: lessons learned from experimental mouse models. Clin Exp Gastroenterol. 2014; 7:297–306.10.2147/CEG.S43737Search in Google Scholar

8. ARRESE M., CABRERA D., KALERGIS AM., FELDSTEIN AE. Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci. 2016; 61(5):1294–1303.10.1007/s10620-016-4049-x494828626841783Search in Google Scholar

9. GILES DA., MORENO-FERNANDEZ ME., DIVANOVIC S. IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression. Curr Drug Targets. 2015; 16(12):1315–1323.10.2174/1389450116666150531153627492985726028039Search in Google Scholar

10. DASARATHY S., DASARATHY S., KHIYAMI A., JOSEPH R., LOPEZ R., MCCULLOUGH AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009; 51(6):1061–1067.10.1016/j.jhep.2009.09.001613614819846234Search in Google Scholar

11. SHANNON A., ALKHOURI N., CARTER-KENT C., MONTI L., DEVITO R., LOPEZ R., et al. Ultrasonographic quantitative estimation of hepatic steatosis in children with NAFLD. J Pediatr Gastroenterol Nutr. 2011; 53(2):190–195.10.1097/MPG.0b013e31821b4b61314450521788761Search in Google Scholar

12. YOUNOSSI ZM., KOENIG AB., ABDELATIF D., FAZEL Y., HENRY L., WYMER M. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1):73–84.10.1002/hep.28431Search in Google Scholar

13. DYSON JK., ANSTEE QM., MCPHERSON S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014; 5(3):211–218.10.1136/flgastro-2013-100403407866625018867Search in Google Scholar

14. JENNISON E., PATEL J., SCORLETTI E., BYRNE CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019; 95(1124):314–322.10.1136/postgradmedj-2018-13631631085617Search in Google Scholar

15. SANNA C., ROSSO C., MARIETTI M., BUGIANESI E. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci. 2016; 17(5):717.10.3390/ijms17050717488153927187365Search in Google Scholar

16. STOJSAVLJEVIC S., PALCIC MG., JUKIC LV., DUVNJAK LS, DUVNJAK M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20(48):18070–18091.10.3748/wjg.v20.i48.18070427794825561778Search in Google Scholar

17. SUTTI S., ALBANO E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2020; 17(2):81–92.10.1038/s41575-019-0210-2722295331605031Search in Google Scholar

18. BRAUNERSREUTHER V., VIVIANI GL., MACH F., MONTECUCCO F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012; 18(8):727–735.10.3748/wjg.v18.i8.727328613522371632Search in Google Scholar

19. KREMER M., THOMAS E., MILTON RJ., PERRY AW., VAN ROOIJEN N., WHEELER MD. Kupffer cell and interleukin-12 dependent loss of natural killer T cells in hepatosteatosis. Hepatology. 2010; 51(1):130–141.10.1002/hep.23292376196220034047Search in Google Scholar

20. AJMERA V., PERITO ER., BASS NM., TERRAULT NA., YATES KP., GILL R., et al. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology. 2017; 65(1):65–77.10.1002/hep.28776519193227532276Search in Google Scholar

21. TARANTINO G., CITRO V, CONFORTI P, BALSANO C, CAPONE D. Is there a link between basal metabolic rate, spleen volume and hepatic growth factor levels in patients with obesity-related NAFLD? JCM. 2019; 8:1510.10.3390/jcm8101510Search in Google Scholar

22. XIAO G., ZHU S., XIAO X., YAN L., YANG J., WU G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatol. 2017; 66:1486–501.10.1002/hep.2930228586172Search in Google Scholar

23. CLEVELAND E., BANDY A., VANWAGNER LB. Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken). 2018/04/20 ed. 2018;11:98–104.10.1002/cld.716Search in Google Scholar